Table 1.
Characteristics of the study population according to predictors expressed with proportions or means including the 95% confidence interval.
| Predictors | N 1 | Proportion % (95% CI) | Predictors | N | Mean (95% CI) | ||
|---|---|---|---|---|---|---|---|
| Smoker | Yes | 24 | 12 (7.8–17.3) | Age (years) | ≤43.3 | 100 | 32.6 (31.3–33.8) |
| No | 176 | 79.5 (73.2–84.9) | >43.3 | 100 | 53.8 (52.4–55.2) | ||
| Pre-booster concomitant medication | Yes | 73 | 36.5 (29.8–43.6) | 2 BMI (kg/m2) | ≤25.2 | 100 | 22.2 (21.8–22.7) |
| No | 127 | 63.5 (56.4–70.2) | >25.2 | 100 | 29.6 (28.8–30.3) | ||
| Related adverse events | Yes | 44 | 22 (16.5–28.4) | Time since last dose (years) | ≤33.9 | 100 | 17.1 (15.5–18.7) |
| No | 156 | 78 (71.6–83.5) | >33.9 | 100 | 45.0 (43.5–46.4) | ||
| Needle length (mm) | 16 | 150 | 75 (68.4–80.8) | Pre-vaccination anti-DT 3 GMCs (IU/mL) | ≤0.05 | 101 | 0.03 (0.02–0.03) |
| 25 | 50 | 25 (19.2–31.6) | >0.05 | 99 | 0.11 (0.09–0.12) |
1 N: number of subjects; 2 BMI: body mass index; 3 anti-DT anti-diphtheria toxin antibodies, 3 IU: international unit, 3 GMC: geometric mean concentration. Note: males and females as well as both vaccines at a 1:1 ratio, i.e., proportions of 50% (95% CI 42.9–57.1%).